Ontology highlight
ABSTRACT: Aims
To confirm superiority on glycaemic control by switching from sitagliptin to liraglutide 1.8?mg/d versus continued sitagliptin.Materials and methods
A randomized, multicentre, double-blind, double-dummy, active-controlled trial across 86 office- or hospital-based sites in North America, Europe and Asia. Subjects with type 2 diabetes who had inadequate glycaemic control (glycated haemoglobin [HbA1c] 7.5-9.5% on sitagliptin (100?mg/d) and metformin (?1500?mg daily) for ?90?days were randomized to either switch to liraglutide (n?=?203) or continue sitagliptin (n?=?204), both with metformin. The primary endpoint was change in HbA1c from baseline to week 26. Change in body weight was a confirmatory secondary endpoint.Results
Greater reduction in mean HbA1c was achieved with liraglutide than with continued sitagliptin [-1.14% vs. -0.54%; estimated mean treatment difference (ETD): -0.61% (95% CI -0.82 to -0.40; p?ConclusionsSubjects insufficiently controlled with sitagliptin who switch to liraglutide can obtain clinically relevant reductions in glycaemia and body weight, without compromising safety. A switch from sitagliptin to liraglutide provides an option for improved management of type 2 diabetes while still allowing patients to remain on dual therapy.
SUBMITTER: Bailey TS
PROVIDER: S-EPMC5129465 | biostudies-literature | 2016 Dec
REPOSITORIES: biostudies-literature
Diabetes, obesity & metabolism 20160914 12
<h4>Aims</h4>To confirm superiority on glycaemic control by switching from sitagliptin to liraglutide 1.8 mg/d versus continued sitagliptin.<h4>Materials and methods</h4>A randomized, multicentre, double-blind, double-dummy, active-controlled trial across 86 office- or hospital-based sites in North America, Europe and Asia. Subjects with type 2 diabetes who had inadequate glycaemic control (glycated haemoglobin [HbA1c] 7.5-9.5% on sitagliptin (100 mg/d) and metformin (≥1500 mg daily) for ≥90 day ...[more]